Trial Outcomes & Findings for Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (NCT NCT00287729)

NCT ID: NCT00287729

Last Updated: 2017-04-17

Results Overview

Mean Change in Percent Predicted Forced Vital Capacity (FVC) as measured from baseline to week 72. It is calculated as the simple difference between baseline Percent Predicted FVC measurements and week 72 Percent Predicted FVC measurements.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

344 participants

Primary outcome timeframe

Baseline to week 72

Results posted on

2017-04-17

Participant Flow

Participant milestones

Participant milestones
Measure
Pirfenidone (2403 mg/d)
pirfenidone, total daily dose of 2403 mg/day, given as 3 divided doses 3 times/day
Placebo
placebo equivalent, given as 3 divided doses 3 times/day
Overall Study
STARTED
171
173
Overall Study
COMPLETED
137
142
Overall Study
NOT COMPLETED
34
31

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Pirfenidone (2403 mg/d)
n=171 Participants
pirfenidone, total daily dose of 2403 mg/day, given as 3 divided doses 3 times/day
Placebo
n=173 Participants
placebo equivalent, given as 3 divided doses 3 times/day
Total
n=344 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
70 Participants
n=5 Participants
61 Participants
n=7 Participants
131 Participants
n=5 Participants
Age, Categorical
>=65 years
101 Participants
n=5 Participants
112 Participants
n=7 Participants
213 Participants
n=5 Participants
Age, Continuous
66.8 years
STANDARD_DEVIATION 7.90 • n=5 Participants
67.0 years
STANDARD_DEVIATION 7.80 • n=7 Participants
66.9 years
STANDARD_DEVIATION 7.84 • n=5 Participants
Sex: Female, Male
Female
48 Participants
n=5 Participants
49 Participants
n=7 Participants
97 Participants
n=5 Participants
Sex: Female, Male
Male
123 Participants
n=5 Participants
124 Participants
n=7 Participants
247 Participants
n=5 Participants
Region of Enrollment
United States
148 participants
n=5 Participants
150 participants
n=7 Participants
298 participants
n=5 Participants
Region of Enrollment
Europe
23 participants
n=5 Participants
22 participants
n=7 Participants
45 participants
n=5 Participants
Region of Enrollment
Australia
0 participants
n=5 Participants
1 participants
n=7 Participants
1 participants
n=5 Participants

PRIMARY outcome

Timeframe: Baseline to week 72

Population: A modified intent-to-treat population of all randomized patients who received any amount of study drug is the primary population for efficacy and safety analyses. Missing FVC data due to death were assigned the worst rank and missing FVC data due to reasons other than death were imputed using the SSD method.

Mean Change in Percent Predicted Forced Vital Capacity (FVC) as measured from baseline to week 72. It is calculated as the simple difference between baseline Percent Predicted FVC measurements and week 72 Percent Predicted FVC measurements.

Outcome measures

Outcome measures
Measure
Pirfenidone (2403 mg/d)
n=171 Participants
pirfenidone, total daily dose of 2403 mg/day, given as 3 divided doses 3 times/day
Placebo
n=173 Participants
placebo equivalent, given as 3 divided doses 3 times/day
Absolute Change in Percent Predicted Forced Vital Capacity(FVC)
-9 Change in Percent Predicted FVC
Standard Deviation 19.58
-10 Change in Percent Predicted FVC
Standard Deviation 19.12

SECONDARY outcome

Timeframe: Baseline to week 72

Population: A modified intent-to-treat population of all randomized patients who received any amount of study drug is used as the primary population for all efficacy and safety analyses. Missing data were imputed by the SSD method if the patient was alive and imputed to 0% if the patient died before the protocol-specified time point.

Based on the change in baseline percent predicted FVC at week 72, patients were assigned to 1 of 5 categories: mild decline (\<10% but \>=0% decline), moderate decline (\<20% but \>=10% decline), severe decline (\>=20% decline), mild improvement (\>0% but \<10% improvement), or moderate improvement (\>=10% improvement). Those who died or had a lung transplant before Week 72 were included in the severe decline category. The results indicate the number of patients who experience Categorical Change in Percent Predicted Forced Vital Capacity.

Outcome measures

Outcome measures
Measure
Pirfenidone (2403 mg/d)
n=171 Participants
pirfenidone, total daily dose of 2403 mg/day, given as 3 divided doses 3 times/day
Placebo
n=173 Participants
placebo equivalent, given as 3 divided doses 3 times/day
Categorical Assessment of Absolute Change in Percent Predicted Forced Vital Capacity
Decline <10% but > 0%
88 Patients
89 Patients
Categorical Assessment of Absolute Change in Percent Predicted Forced Vital Capacity
Decline >=20% or death or lung transplantation
20 Patients
23 Patients
Categorical Assessment of Absolute Change in Percent Predicted Forced Vital Capacity
Decline <20% but >= 10%
19 Patients
23 Patients
Categorical Assessment of Absolute Change in Percent Predicted Forced Vital Capacity
Improvement of >=0% but <10%
41 Patients
33 Patients
Categorical Assessment of Absolute Change in Percent Predicted Forced Vital Capacity
Improvement of >=10%
3 Patients
5 Patients

SECONDARY outcome

Timeframe: Baseline to Week 72

Population: A modified intent-to-treat population of all randomized patients who received any amount of study drug is used as the primary population for efficacy and safety analyses.

Progression is defined as the first occurrence of a 10% absolute decline from baseline in percent predicted Forced Vital Capacity, a 15% absolute decline from baseline in percent predicted hemoglobin(Hgb)-corrected carbon monoxide diffusing capacity (DLco), or, death.

Outcome measures

Outcome measures
Measure
Pirfenidone (2403 mg/d)
n=171 Participants
pirfenidone, total daily dose of 2403 mg/day, given as 3 divided doses 3 times/day
Placebo
n=173 Participants
placebo equivalent, given as 3 divided doses 3 times/day
Progression-free Survival
Death or Disease Progression
54 Number of Patients with Progression
60 Number of Patients with Progression
Progression-free Survival
Decline in percent predicted FVC >=10%
31 Number of Patients with Progression
41 Number of Patients with Progression
Progression-free Survival
Decline in percent predicted DLco >=15%
10 Number of Patients with Progression
9 Number of Patients with Progression
Progression-free Survival
Death Before Disease Progression
13 Number of Patients with Progression
10 Number of Patients with Progression

SECONDARY outcome

Timeframe: Baseline to Week 72

Population: A modified intent-to-treat population of all randomized patients who received any amount of study drug is used as the primary population for efficacy and safety analyses. Missing data were imputed by the SSD method if the patient was alive and imputed to 0 meters if the patient had died before the protocol-specified time point.

The change from Baseline to week 72 in distance walked during the 6-Minute Walk Test. This measure was calculated as the simple difference between baseline distanced walked over 6 minutes and week 72 distance walked over 6 minutes as measured in meters (m).

Outcome measures

Outcome measures
Measure
Pirfenidone (2403 mg/d)
n=171 Participants
pirfenidone, total daily dose of 2403 mg/day, given as 3 divided doses 3 times/day
Placebo
n=173 Participants
placebo equivalent, given as 3 divided doses 3 times/day
Change in the Six-Minute Walk Test (6MWT) Distance
-45 Change in Distance Walked in Meters
Standard Deviation 140
-77 Change in Distance Walked in Meters
Standard Deviation 128

SECONDARY outcome

Timeframe: Baseline to Week 72

Population: A modified intent-to-treat population of all randomized patients who received any amount of study drug is used as the primary population for efficacy and safety analyses. Missing data were imputed by the SSD method if the patient was alive and imputed to 83% if the patient died before the protocol-specified time point.

The change from baseline to week 72 in worst oxygen saturation during the 6-Minute Walk Test as measure by Pulse Oximetry (SpO2) Level. It is calculated as the simple difference between baseline SpO2 measurements and week 72 SpO2 measurements.

Outcome measures

Outcome measures
Measure
Pirfenidone (2403 mg/d)
n=171 Participants
pirfenidone, total daily dose of 2403 mg/day, given as 3 divided doses 3 times/day
Placebo
n=173 Participants
placebo equivalent, given as 3 divided doses 3 times/day
Change in Worst Oxygen Saturation by Pulse Oximetry (SpO2) Measurement Observed During the 6-Minute Walk Test
-1.9 Change,Worst Oxygen Saturation (Percent)
Standard Deviation 3.83
-1.3 Change,Worst Oxygen Saturation (Percent)
Standard Deviation 6.63

SECONDARY outcome

Timeframe: Baseline to Week 72

Population: A modified intent-to-treat population of all randomized patients who received any amount of study drug is used as the primary population for efficacy and safety analyses. Missing data were imputed by the SSD method if the patient was alive and imputed to 0% if the patient died before the protocol-specified time point.

The change from baseline to week 72 in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs. It is calculated as the simple difference between baseline DLco measurements and week 72 DLco measurements.

Outcome measures

Outcome measures
Measure
Pirfenidone (2403 mg/d)
n=171 Participants
pirfenidone, total daily dose of 2403 mg/day, given as 3 divided doses 3 times/day
Placebo
n=173 Participants
placebo equivalent, given as 3 divided doses 3 times/day
Change in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs
-9.8 Change in Percent Predicted DLco
Standard Deviation 12.61
-9.2 Change in Percent Predicted DLco
Standard Deviation 13.24

SECONDARY outcome

Timeframe: Baseline to Week 72

Population: A modified intent-to-treat population of all randomized patients who received any amount of study drug is used as the primary population for efficacy and safety analyses. Missing data were imputed by the SSD method if the patient was alive and imputed to a score of 120 if the patient died before the protocol-specified time point.

The mean change from baseline to week 72 in Dyspnea score was measured by the University of San Diego Shortness of Breath Questionnaire (UCSD SOBQ). The SOBQ is used to assess shortness of breath with various activities of daily living (for example, brushing ones teeth or mowing the lawn). Patients rated the severity of their shortness of breath experienced on an average day during the past week on a 6 point scale (0 to 5),with 0= not at all breathless, 4= severely breathless and 5= Maximally or unable to do because of breathlessness.

Outcome measures

Outcome measures
Measure
Pirfenidone (2403 mg/d)
n=171 Participants
pirfenidone, total daily dose of 2403 mg/day, given as 3 divided doses 3 times/day
Placebo
n=173 Participants
placebo equivalent, given as 3 divided doses 3 times/day
Change in Dyspnea Score
11.9 Change in Dyspnea Score
Standard Deviation 24.72
13.9 Change in Dyspnea Score
Standard Deviation 27.89

SECONDARY outcome

Timeframe: Time to acute IPF exacerbation, IPF-related death, lung transplant or respiratory hospitalization, whichever comes first.

Population: A modified intent-to-treat population of all randomized patients who received any amount of study drug is used as the primary population for efficacy and safety analyses.

Worsening of IPF was defined by the occurrence of any of the following events: Acute IPF exacerbation, IPF-related death, Lung transplantation, or Respiratory hospitalization.

Outcome measures

Outcome measures
Measure
Pirfenidone (2403 mg/d)
n=171 Participants
pirfenidone, total daily dose of 2403 mg/day, given as 3 divided doses 3 times/day
Placebo
n=173 Participants
placebo equivalent, given as 3 divided doses 3 times/day
Worsening of IPF
Woresening IPF
24 Number of Patients Who Worsened
32 Number of Patients Who Worsened
Worsening of IPF
Acute IPF exacerbation
2 Number of Patients Who Worsened
1 Number of Patients Who Worsened
Worsening of IPF
IPF-related death
3 Number of Patients Who Worsened
6 Number of Patients Who Worsened
Worsening of IPF
Lung transplantation
2 Number of Patients Who Worsened
2 Number of Patients Who Worsened
Worsening of IPF
Respiratory hospitalization
17 Number of Patients Who Worsened
23 Number of Patients Who Worsened
Worsening of IPF
Patients Censored
146 Number of Patients Who Worsened
141 Number of Patients Who Worsened

Adverse Events

Pirfenidone (2403 mg/d)

Serious events: 53 serious events
Other events: 169 other events
Deaths: 0 deaths

Placebo

Serious events: 51 serious events
Other events: 170 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Pirfenidone (2403 mg/d)
n=171 participants at risk
pirfenidone, total daily dose of 2403 mg/day, given as 3 divided doses 3 times/day
Placebo
n=173 participants at risk
placebo equivalent, given as 3 divided doses 3 times/day
Cardiac disorders
Angina Pectoris
0.58%
1/171
0.58%
1/173
Cardiac disorders
Angina Unstable
0.00%
0/171
0.58%
1/173
Cardiac disorders
Atrial Fibrillation
1.2%
2/171
0.58%
1/173
Cardiac disorders
Cardiac Failure Congestive
0.58%
1/171
0.58%
1/173
Cardiac disorders
Coronary Artery Disease
3.5%
6/171
0.00%
0/173
Cardiac disorders
Coronary Artery Stenosis
0.00%
0/171
0.58%
1/173
Cardiac disorders
Myocardial Infarction
0.58%
1/171
0.00%
0/173
Cardiac disorders
Sick Sinus Syndrome
1.2%
2/171
0.00%
0/173
Cardiac disorders
Supraventricular Tachycardia
0.58%
1/171
0.00%
0/173
Cardiac disorders
Ventricular Tachycardia
0.58%
1/171
0.00%
0/173
Gastrointestinal disorders
Colitis
1.2%
2/171
0.00%
0/173
Gastrointestinal disorders
Diverticular Perforation
0.58%
1/171
0.58%
1/173
Gastrointestinal disorders
Ileus
0.00%
0/171
0.58%
1/173
Gastrointestinal disorders
Pancreatitis
0.58%
1/171
0.00%
0/173
General disorders
Asthenia
0.00%
0/171
0.58%
1/173
General disorders
Chest Pain
0.58%
1/171
0.00%
0/173
General disorders
Multi Organ Failure
0.58%
1/171
0.00%
0/173
General disorders
Non-Cardiac Chest Pain
0.00%
0/171
0.58%
1/173
General disorders
Pyrexia
0.58%
1/171
0.00%
0/173
Hepatobiliary disorders
Cholelithiasis
0.58%
1/171
0.00%
0/173
Hepatobiliary disorders
Hepatitis
0.58%
1/171
0.00%
0/173
Infections and infestations
Abdominal Abscess
0.00%
0/171
0.58%
1/173
Infections and infestations
Bronchiectasis
0.00%
0/171
0.58%
1/173
Infections and infestations
Bronchitis
0.00%
0/171
2.9%
5/173
Infections and infestations
Bronchitis Viral
0.58%
1/171
0.00%
0/173
Infections and infestations
Cholecystitis Infective
0.58%
1/171
0.00%
0/173
Infections and infestations
Chronic Sinusitis
0.58%
1/171
0.00%
0/173
Infections and infestations
Clostridium Difficile Colitis
0.00%
0/171
0.58%
1/173
Infections and infestations
Diverticulitis
0.00%
0/171
0.58%
1/173
Infections and infestations
Lobar Pneumonia
4.1%
7/171
4.0%
7/173
Infections and infestations
Pneumonia
0.58%
1/171
0.00%
0/173
Infections and infestations
Respiratory Tract Infection
0.58%
1/171
0.00%
0/173
Infections and infestations
Septic Shock
0.58%
1/171
0.00%
0/173
Infections and infestations
Sinusitis
0.00%
0/171
0.58%
1/173
Infections and infestations
Urinary Tract Infection
0.58%
1/171
0.58%
1/173
Infections and infestations
Viral Infection
0.00%
0/171
0.58%
1/173
Infections and infestations
Viral Upper Respiratory Tract Infection
0.58%
1/171
0.00%
0/173
Injury, poisoning and procedural complications
Ankle Fracture
0.58%
1/171
0.00%
0/173
Injury, poisoning and procedural complications
Concussion
0.00%
0/171
0.58%
1/173
Injury, poisoning and procedural complications
Endotracheal Intubation Complication
0.58%
1/171
0.00%
0/173
Injury, poisoning and procedural complications
Fall
1.2%
2/171
0.58%
1/173
Injury, poisoning and procedural complications
Femur Fracture
0.58%
1/171
0.00%
0/173
Injury, poisoning and procedural complications
Hip Fracture
1.2%
2/171
0.00%
0/173
Metabolism and nutrition disorders
Pelvic Fracture
0.58%
1/171
0.00%
0/173
Injury, poisoning and procedural complications
Psychosis Postoperative
0.58%
1/171
0.00%
0/173
Injury, poisoning and procedural complications
Radius Fracture
0.58%
1/171
0.00%
0/173
Injury, poisoning and procedural complications
Spinal Compression Fracture
0.58%
1/171
0.00%
0/173
Investigations
Hepatic Enzyme Increased
0.00%
0/171
0.58%
1/173
Investigations
Liver Function Test Abnormal
1.2%
2/171
0.00%
0/173
Investigations
Weight Decreased
0.00%
0/171
0.58%
1/173
Metabolism and nutrition disorders
Dehydration
0.58%
1/171
0.00%
0/173
Metabolism and nutrition disorders
Diabetes Mellitus Inadequate Control
0.00%
0/171
0.58%
1/173
Metabolism and nutrition disorders
Hyperkalaemia
0.58%
1/171
0.00%
0/173
Metabolism and nutrition disorders
Hypoglycaemia
0.58%
1/171
0.00%
0/173
Metabolism and nutrition disorders
Hyponatraemia
0.58%
1/171
0.00%
0/173
Musculoskeletal and connective tissue disorders
Bursitis
0.58%
1/171
0.00%
0/173
Musculoskeletal and connective tissue disorders
Intervertebral Disc Protrusion
1.2%
2/171
0.00%
0/173
Musculoskeletal and connective tissue disorders
Myalgia
0.58%
1/171
0.00%
0/173
Musculoskeletal and connective tissue disorders
Osteoarthritis
0.00%
0/171
0.58%
1/173
Musculoskeletal and connective tissue disorders
Pathological Fracture
0.00%
0/171
0.58%
1/173
Musculoskeletal and connective tissue disorders
Rotator Cuff Syndrome
0.00%
0/171
0.58%
1/173
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder Cancer
0.58%
1/171
0.58%
1/173
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder Transitional Cell Carcinoma
0.00%
0/171
0.58%
1/173
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast Cancer
0.00%
0/171
0.58%
1/173
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon Cancer Stage II
0.58%
1/171
0.00%
0/173
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to Bone
0.58%
1/171
0.00%
0/173
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to Lung
0.58%
1/171
0.00%
0/173
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastastic Neoplasm
0.00%
0/171
0.58%
1/173
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic Squamous Cell Carcinoma
0.00%
0/171
0.58%
1/173
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian Cancer
0.00%
0/171
0.58%
1/173
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic Carcinoma
0.58%
1/171
0.00%
0/173
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate Cancer
1.2%
2/171
0.00%
0/173
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small Cell Lung Cancer Stage Unspecified
0.58%
1/171
0.58%
1/173
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous Cell Carcinoma
0.00%
0/171
0.58%
1/173
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional Cell Carcinoma
0.00%
0/171
1.2%
2/173
Nervous system disorders
Apraxia
0.00%
0/171
0.58%
1/173
Nervous system disorders
Carotid Artery Stenosis
0.58%
1/171
0.58%
1/173
Nervous system disorders
Cerebrovascular Accident
0.58%
1/171
0.00%
0/173
Nervous system disorders
Sciatica
0.00%
0/171
0.58%
1/173
Nervous system disorders
Transient Ischaemic Attack
0.00%
0/171
0.58%
1/173
Psychiatric disorders
Mental Status Changes
0.00%
0/171
0.58%
1/173
Psychiatric disorders
Suicidal Ideation
0.58%
1/171
0.00%
0/173
Renal and urinary disorders
Bladder Neck Obstruction
0.58%
1/171
0.00%
0/173
Renal and urinary disorders
Glomerulonephritis Rapidly Progressive
0.00%
0/171
0.58%
1/173
Renal and urinary disorders
Mesangioproliferative Glomerulonephritis
0.00%
0/171
0.58%
1/173
Renal and urinary disorders
Nephrolithiasis
1.2%
2/171
0.00%
0/173
Renal and urinary disorders
Renal Failure Acute
1.2%
2/171
1.2%
2/173
Reproductive system and breast disorders
Benign Prostatic Hyperpasia
0.00%
0/171
0.58%
1/173
Respiratory, thoracic and mediastinal disorders
Acute Respiratory Failure
1.2%
2/171
1.7%
3/173
Respiratory, thoracic and mediastinal disorders
Chronic Obstructive Pulmonary Disease
0.00%
0/171
0.58%
1/173
Respiratory, thoracic and mediastinal disorders
Dyspnoea
0.58%
1/171
0.58%
1/173
Respiratory, thoracic and mediastinal disorders
Haemoptysis
0.00%
0/171
0.58%
1/173
Respiratory, thoracic and mediastinal disorders
Hypoxia
0.00%
0/171
1.2%
2/173
Respiratory, thoracic and mediastinal disorders
Idiopathic Pulmonary Fibrosis
7.6%
13/171
9.8%
17/173
Respiratory, thoracic and mediastinal disorders
Pleural Effusion
0.58%
1/171
0.00%
0/173
Respiratory, thoracic and mediastinal disorders
Pneumothorax
0.58%
1/171
0.58%
1/173
Respiratory, thoracic and mediastinal disorders
Productive Cough
0.58%
1/171
0.00%
0/173
Respiratory, thoracic and mediastinal disorders
Respiratory Arrest
0.00%
0/171
0.58%
1/173
Respiratory, thoracic and mediastinal disorders
Respiratory Distress
0.00%
0/171
0.58%
1/173
Respiratory, thoracic and mediastinal disorders
Respiratory Failure
2.3%
4/171
3.5%
6/173
Vascular disorders
Aortic Aneurysm
0.00%
0/171
0.58%
1/173
Vascular disorders
Hypertension
0.00%
0/171
1.2%
2/173
Vascular disorders
Hypotension
1.2%
2/171
0.58%
1/173
Vascular disorders
Malignant Hypertension
0.58%
1/171
0.00%
0/173
Vascular disorders
Thrombosis
0.58%
1/171
0.00%
0/173

Other adverse events

Other adverse events
Measure
Pirfenidone (2403 mg/d)
n=171 participants at risk
pirfenidone, total daily dose of 2403 mg/day, given as 3 divided doses 3 times/day
Placebo
n=173 participants at risk
placebo equivalent, given as 3 divided doses 3 times/day
Metabolism and nutrition disorders
Anorexia
10.5%
18/171
3.5%
6/173
Psychiatric disorders
Anxiety
3.5%
6/171
5.8%
10/173
Musculoskeletal and connective tissue disorders
Arthralgia
9.4%
16/171
6.4%
11/173
Musculoskeletal and connective tissue disorders
Back Pain
12.3%
21/171
8.7%
15/173
Respiratory, thoracic and mediastinal disorders
Cough
29.8%
51/171
31.2%
54/173
Metabolism and nutrition disorders
Decreased appetite
7.6%
13/171
5.2%
9/173
Psychiatric disorders
Depression
5.8%
10/171
4.0%
7/173
Nervous system disorders
Dizziness
17.5%
30/171
10.4%
18/173
Respiratory, thoracic and mediastinal disorders
Dyspnoea
16.4%
28/171
19.7%
34/173
Nervous system disorders
Headache
16.4%
28/171
14.5%
25/173
Respiratory, thoracic and mediastinal disorders
Idiopathic Pulmonary Fibrosis
18.1%
31/171
23.1%
40/173
Psychiatric disorders
Insomnia
7.0%
12/171
6.4%
11/173
Musculoskeletal and connective tissue disorders
Musculoskeletal Pain
3.5%
6/171
5.2%
9/173
Respiratory, thoracic and mediastinal disorders
Nasal Congestion
7.0%
12/171
8.1%
14/173
Musculoskeletal and connective tissue disorders
Pain in Extremity
6.4%
11/171
6.4%
11/173
Respiratory, thoracic and mediastinal disorders
Pharyngolaryngeal pain
4.7%
8/171
6.4%
11/173
Skin and subcutaneous tissue disorders
Photosensitivity reaction
9.9%
17/171
2.3%
4/173
Respiratory, thoracic and mediastinal disorders
Postnasal Drip
4.1%
7/171
6.9%
12/173
Respiratory, thoracic and mediastinal disorders
Productive Cough
6.4%
11/171
1.7%
3/173
Skin and subcutaneous tissue disorders
Pruritus
5.8%
10/171
4.6%
8/173
Skin and subcutaneous tissue disorders
Rash
33.9%
58/171
12.7%
22/173
Respiratory, thoracic and mediastinal disorders
Respiratory Failure
2.9%
5/171
4.6%
8/173
Respiratory, thoracic and mediastinal disorders
Rhinitis Allergic
6.4%
11/171
2.3%
4/173

Additional Information

Bill Bradford, MD, PhD

InterMune, Inc.

Phone: (415) 466-2200

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: OTHER